Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
featured
CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

  • 84 views
  • 08 Nov, 2020
  • 1 location
featured
Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias

Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias

  • 6 views
  • 08 Nov, 2020
  • 1 location
featured
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

  • 368 views
  • 08 Nov, 2020
  • 1 location
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with

  • 2 views
  • 27 Jan, 2021
  • 32 locations
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in

  • 10 views
  • 23 Jan, 2021
  • 35 locations
Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients

complete surgical resection and progressing to cytotoxic chemotherapy will receive Sorafenib plus metronomic chemotherapy as treatment.The aim of this phase II trial is to evaluate the clinical

paclitaxel
metastasis
measurable disease
cytotoxic chemotherapy
heparin
  • 67 views
  • 07 Nov, 2020
  • 1 location
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

number of patients who may benefit from therapy. The SHARP trial established the survival benefit of Sorafenib in Advanced HCC but the results yet remain humble. The need for more effective

gemcitabine
platelet count
cancer
measurable disease
systemic therapy
  • 14 views
  • 07 Nov, 2020
  • 1 location
Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether giving gemcitabine together

tumor cells
gemcitabine
adenocarcinoma
metastatic pancreatic cancer
metastasis
  • 25 views
  • 07 Nov, 2020
  • 1 location
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

models of sarcoma (7,8). For these reasons, inhibition of VEGFR seems to be a reasonable approach to explore in the treatment of STS. Sorafenib (BAY 43-9006) is an orally available, small

small molecule
gemcitabine
immunomodulators
ewing's sarcoma
platelet count
  • 13 views
  • 07 Nov, 2020
  • 1 location
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy

chemotherapy regimens of proven benefit (7). The purpose of this study is to determine if multiple-relapsed chemorefractory pts may benefit from sorafenib monotherapy.

gemcitabine
cancer chemotherapy
carcinoma
renal function tests
measurable disease
  • 54 views
  • 07 Nov, 2020
  • 1 location